Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel in Breast Cancer Patients: A Multicentric, Open-label, Non-randomized Concurrent Control, Non-inferiority Trial

NCT03123770 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT03123770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03123770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel in Breast Cancer Patients: A Multicentric, Open-label, Non-randomized Concurrent Control, Non-inferiority Trial
Lead sponsor
Zhejiang University
Phase
Phase 4
Overall status
Unknown status
Start date
December 31, 2016
Completion date
December 31, 2021
Enrollment
384 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer